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INTRODUCTION {#lio2288-sec-0001}
============

Cochlear implantation has revolutionized the care for children and adults with deafness. The first surgery for implantation of a single channel cochlear implant (CI) occurred in 1961, by House and Doyle, and was followed by the first multichannel CI in 1978.[1](#lio2288-bib-0001){ref-type="ref"}

In the intervening six decades, the goals for CI recipients\' sound perception have advanced and continue to be refined. Initially, the goal was perception of sound, then speech recognition, and serviceable hearing. Today, the goal is to improve quality of life through excellent speech recognition, functional hearing in noise, and the ability to appreciate nuanced sound with precisely coded temporal elements like music. In addition to including adults and children with severe to profound sensorineural hearing loss (SNHL) not improved with hearing aids, CI candidacy criteria has also changed considerably and now includes children as young as 12 months old (and younger under certain conditions) and adults with retained low frequency hearing via the hybrid CI which uses a combination of electrical and acoustic stimulation.[2](#lio2288-bib-0002){ref-type="ref"}

CIs allow children with deafness to attain speech outcomes on par with their normal‐hearing peers.[3](#lio2288-bib-0003){ref-type="ref"} In addition, CIs improve quality of life for adults with hearing loss as well as children with hearing loss and their families.[4](#lio2288-bib-0004){ref-type="ref"}, [5](#lio2288-bib-0005){ref-type="ref"} While data show that the majority of CI users obtain excellent hearing and speech recognition in noise outcomes, a minority do not achieve expected hearing levels. This variability occurs for both children[3](#lio2288-bib-0003){ref-type="ref"} and adults.[6](#lio2288-bib-0006){ref-type="ref"} Since the early years of cochlear implantation there have been attempts to determine factors why some users experience better, or worse, outcomes than predicted preoperatively.[7](#lio2288-bib-0007){ref-type="ref"}

Some of the strongest predictors of postoperative CI outcomes are clinical factors associated with hearing loss including duration of deafness, socioeconomic status, and preoperative audiometric thresholds.[8](#lio2288-bib-0008){ref-type="ref"} The largest studies of clinical factors predicting postoperative CI outcomes showed that two different statistical models that considered up to nine different clinical factors simultaneously could account for 10.5% or 22% of variance in postoperative speech outcomes.[6](#lio2288-bib-0006){ref-type="ref"}, [9](#lio2288-bib-0009){ref-type="ref"} A less complex and more encompassing measure to explain postoperative CI outcomes has so far been out of reach.

From a clinical perspective, there are few relative contraindications to cochlear implantation, but there is general agreement that outcomes are poor in patients with an absent cochlear nerve or severely narrowed internal auditory canal.[10](#lio2288-bib-0010){ref-type="ref"} The lack of a cochlear nerve would prevent the electrical stimulus from the CI from reaching the brainstem. For these patients, auditory brainstem implantation has led to improved speech outcomes.[11](#lio2288-bib-0011){ref-type="ref"}

As opposed to a complete lack of an auditory nerve, a decreased number of spiral ganglion (SG) neurons has also been hypothesized to affect CI outcomes. Otte et al and Nadol et al evaluated spiral ganglion counts in temporal bones of individuals with hearing loss of various causes.[12](#lio2288-bib-0012){ref-type="ref"}, [13](#lio2288-bib-0013){ref-type="ref"} These authors identified wide variability in SG counts and predicted that this may affect CI outcomes. More recently, Seyyedi et al were the first to show that SG counts significantly predicts CI outcomes in six patients with matched temporal bones.[14](#lio2288-bib-0014){ref-type="ref"} Therefore, the binary presence or absence of auditory nerve fibers appears to play an important role in CI outcomes. A growing set of published data is revealing that differences in auditory nerve or spiral ganglion health may be just as important.

In this review, we will examine published data which show that qualitative, not solely quantitative, deficits in the auditory nerve affect CI outcomes. As opposed to a complete lack of an auditory nerve, it follows that individuals with a damaged, altered, or relatively nonfunctional auditory nerve or spiral ganglion could also have relatively poor CI outcomes. These individuals may have poor spiral ganglion or auditory nerve "health" which may affect outcomes as transmission of neural signal from the stimulating electrode of the CI to the brain. Although currently available data are limited by a small number of patients with inconsistent reporting of CI outcomes, a better understanding of lesions that affect the health of the auditory synapse or auditory nerve will lead to improved CI outcomes.

*Auditory Neuropathy Spectrum Disorder* {#lio2288-sec-0002}
---------------------------------------

Auditory neuropathy is a term used to describe individuals with hearing loss and normally functioning outer hair cells. These individuals will have hearing loss characterized by normal otoacoustic emission (OAE) or cochlear microphonics (CM), indicating normal cochlear function, coupled with abnormal transmission of auditory signal from the synapse to the brain as evidenced by altered auditory brainstem responses (ABRs). The site of lesion causing auditory neuropathy may involve the presynaptic site of release of glutamate in the hair cell, the synapse, the postsynaptic site of neurotransmitter stimulation, the site of initiation of the excitatory postsynaptic potential (EPSP) at the terminal dendrite, or sites along the spiral ganglion that affect transmission of the neural signal along the auditory nerve to the brainstem. In cases of auditory neuropathy, the inner hair cells (IHC) and outer hair cells (OHC) function irrespective of transmission of neural signal, and therefore these lesions result in auditory dyssynchrony. Due to this dyssynchrony, individuals typically will have difficulty with temporal processing of sound resulting in impaired speech perception and sound localization. Because there is an inability to effectively transmit the neural signal to the brain, increasing the sound stimulus level, through hearing aids for instance, may have limited benefit for these patients.

Our understanding of auditory neuropathy continues to expand due to an improved understanding of the molecular physiology of hearing. There is a wide array of physiologic defects in the auditory system that can cause auditory neuropathy, which has led to the introduction of a more broad term for any form of hearing loss and aberrant transmission of neural signal to the brain: auditory neuropathy spectrum disorder (ANSD, reviewed in Moser and Starr[15](#lio2288-bib-0015){ref-type="ref"}). This includes lesions affecting the auditory synapse (auditory synaptopathy) or nerve (auditory neuropathy). Today, ANSD is the preferred and more accurate term but is often used interchangeably with auditory neuropathy or auditory dyssynchrony.

ANSD is caused by both genetic and environmental factors. As will be discussed below, there are 13 known genes that cause ANSD. Environmental causes of ANSD primarily affect the newborn including hyperbilirubinemia, thiamine deficiency, and hypoxia although noise‐induced and age‐related auditory neuropathy affect adults.[15](#lio2288-bib-0015){ref-type="ref"} ANSD is a relatively common cause of hearing loss, affecting between 1.2% and 8.4% of those with hearing loss depending on the population.[16](#lio2288-bib-0016){ref-type="ref"}, [17](#lio2288-bib-0017){ref-type="ref"}, [18](#lio2288-bib-0018){ref-type="ref"}

It has long been hypothesized that individuals with auditory neuropathy are poor CI candidates as transmission of the signal from electrical stimulation of the spiral ganglion provided by the CI could be affected.[19](#lio2288-bib-0019){ref-type="ref"} One large study of subjects with ANSD showed generally positive, though somewhat variable, CI outcomes.[20](#lio2288-bib-0020){ref-type="ref"} Recent studies have confirmed that a nuanced perspective of ANSD is needed to understanding CI outcomes: the exact site of lesion causing hearing loss becomes key in understanding the impact on CI function. Some individuals will have qualitative or quantitative deficits to the spiral ganglion or cochlear nerve and are hypothesized to have poor outcomes with CIs. However, some individuals with ANSD have a genetic lesion affecting the synapse itself, which would be bypassed by a CI and therefore would be expected to have outcomes on par with an individual with a genetic lesion affecting the inner hair cells. For example, one study specifically examined the difference between children with ANSD due to cochlear nerve hypoplasia compared to children with ANSD due to other causes.[21](#lio2288-bib-0021){ref-type="ref"} They found that children with ANSD and cochlear nerve hypoplasia had significantly worse postoperative outcomes. Other studies have shown that the effects of ANSD on the developing cortex may play an important role in CI outcomes.[22](#lio2288-bib-0022){ref-type="ref"} This sort of physiologic site‐of‐lesion analysis is required to improve preoperative counseling for patients with ANSD prior to cochlear implantation.

In this review, we will provide an overview of the sites of lesion caused by genetic insults that cause ANSD and how they are theorized to affect CI outcomes. We will first provide a brief overview of the molecular physiology of the auditory system, with a special attention to how a CI functions within this system. We will then review known genetic lesions that negatively affect spiral ganglion health and review postoperative CI outcome data, when available, for each molecular lesion to the peripheral auditory system. Our aim is to provide an overview of this rapidly advancing field with the goal of improving CI outcomes for all individuals by furthering research in this paradigm for understanding the human auditory system.

*Division of the Peripheral Auditory System into Three Components* {#lio2288-sec-0003}
------------------------------------------------------------------

From the perspective of CI physiology, the human peripheral auditory system can be divided into three conceptual components or partitions: sensory, synaptic, and neural (Fig. [1](#lio2288-fig-0001){ref-type="fig"}). The sensory component is responsible for mechanoelectrical transduction of physical sound waves in to electrical signals through the action of the inner hair cells of the organ of Corti. Deflection of the stereocilia of the hair cells allows ion channels to open and transgression of potassium and calcium into the inner hair cell. The tectorial membrane functions, in concert with the outer hair cells which are fixed to its outer surface, to frequency match and fine tune pitch.

![Overview of the peripheral auditory system with special attention to cochlear implant physiology. The inner hair cell and sensory partition as well as the presynaptic and postsynaptic portion of the synapse are bypassed by the cochlear implant whereas the auditory nerve, spiral ganglion, and brainstem are required for optimal cochlear implant function.](LIO2-4-429-g001){#lio2288-fig-0001}

The synapse of the peripheral auditory system includes the presynaptic site (the base of the hair cell), the synapse itself, and the postsynaptic site (terminal dendrite of the spiral ganglion) (Fig. [1](#lio2288-fig-0001){ref-type="fig"}). The base of inner hair cells interface with terminal processes of spiral ganglion neurons. Presynaptic release of glutamate leads to transmission of sound signal to the spiral ganglion neurons and propagation of the signal centrally. The synapse between the inner hair cell and the spiral ganglion terminal process is composed of several unique features. First, each spiral ganglion neuron receives input from a single inner hair cell but each inner hair cell synapses with several spiral ganglion neurons. After deflection of inner hair cell stereocilia, the mechanoelectrical transduction channels located in the stereocilia allow cation influx. This triggers voltage‐dependent calcium channels near the synapse at the base of the inner hair cells to open. The influx of calcium leads to synaptic vesicle fusion and release of glutamate at the synapse between inner hair cell and spiral ganglion. This synapse is able to encode a high degree of temporal precision because of graded release of glutamatergic vesicles via the ribbon synapse. The ribbon synapse is composed of a long tether which holds synaptic vesicles close to the presynaptic release point in inner hair cells as it is anchored to the cell membrane at the presynaptic active zone in close approximation for release at the synaptic cleft. This presynaptic organization allows for transmission of a signal that is finely temporal encoded (up to 1 kHz) and indefatigable. The synaptic component also includes the postsynaptic glutamate receptors at the terminal dendrite of the spiral ganglion.

The neural partition of the human auditory system (Fig. [1](#lio2288-fig-0001){ref-type="fig"}) is comprised of the distal neurite of the spiral ganglion, the somata of the spiral ganglion which reside in Rosenthal\'s canal, and the central processes of the spiral ganglion which form the cochlear partition of the vestibulocochlear nerve (cranial nerve VIII) and branch to form synapses within the dorsal and ventral cochlear nucleus of the midbrain. Mechanistically the neural partition therefore encompasses spike initiation of the EPSP at the terminal dendrite. Lossless conduction of this signal occurs through the myelinated distal and central dendrites of the spiral ganglion. Central components of the human auditory system include the brainstem and auditory cortex of the temporal lobe which are together responsible for maintenance of the tonotopic organization of sound and processing of sound and speech, respectively.

The CI bypasses the sensory and synaptic partitions by directly stimulating the spiral ganglion somata leading to transmission of electrical signal to the midbrain (Fig. [1](#lio2288-fig-0001){ref-type="fig"}). Thus, it follows that the health of the organ of Corti or synapse will not affect outcomes of cochlear implantation. Conversely, the health of the spiral ganglion (or more generally the auditory nerve), the synapse between the spiral ganglion and the cochlear nucleus, midbrain, or auditory cortex may negatively affect the electrical transmission of sound provided by a CI and theoretically could lead to suboptimal CI outcomes.

EVALUATION OF SPIRAL GANGLION HEALTH {#lio2288-sec-0004}
====================================

In 2002, Sininger and Trautwein wrote that "The exact nature of the lesions in patients with \[auditory neuropathy\] cannot be determined while they are alive."[23](#lio2288-bib-0023){ref-type="ref"} Fortunately, due to advancements in our understanding of electrophysiology of the peripheral auditory system, this is no longer true. ABR and OAEs remain a mainstay of diagnosing ANSD. In some cases, electrocochleography (ECochG), which measures cochlear and early neural responses as acoustic signals are transmitted from the cochlea to the brain, can further confirm the site of lesion.[24](#lio2288-bib-0024){ref-type="ref"} ECochG can be performed via transcanal approach by placing a probe in the tympanic membrane, transtympanically through a probe placed near the round window, or during CI surgery at which time intraoperative intracochlear recordings can be made using electrical stimulus or auditory stimulus.[25](#lio2288-bib-0025){ref-type="ref"}, [26](#lio2288-bib-0026){ref-type="ref"}, [27](#lio2288-bib-0027){ref-type="ref"}, [28](#lio2288-bib-0028){ref-type="ref"} For individuals who have received a CI, the implant itself can be used as both the recording and stimulating electrode[29](#lio2288-bib-0029){ref-type="ref"} including the use of auditory stimuli in patients with residual hearing after cochlear implantation.[30](#lio2288-bib-0030){ref-type="ref"} ECochG measures used to determine the precise site of lesion in individuals with ANSD include cochlear microphonic, summating potential, auditory nerve neurophonic, and adaptation at low and high frequencies.[15](#lio2288-bib-0015){ref-type="ref"}, [24](#lio2288-bib-0024){ref-type="ref"}

Assessment of spiral ganglion health using intraoperative ECochG measurements has become one of the best predictors of CI outcomes. One study showed that up to 47% of postoperative CI outcomes could be predicted from ECochG measures in adults.[26](#lio2288-bib-0026){ref-type="ref"} In pediatric CI recipients, up to 50% of the postoperative outcome variance could be predicted using intraoperative ECochG if clinical factors were also controlled for.[27](#lio2288-bib-0027){ref-type="ref"}, [28](#lio2288-bib-0028){ref-type="ref"} However, the primary disadvantage to intraoperative ECochG is that it is intraoperative: it does not allow for preoperative counseling.

A method for assessing SG health that can be done preoperatively with high reliability would provide valuable patient counseling information prior to implantation and could allow targeted programming and rehabilitation postoperatively for at‐risk individuals in particular. Precision CI programming could be especially important in children who are not able to verbalize satisfaction with hearing. This type of precision programming has already shown some progress for patients with ANSD.[31](#lio2288-bib-0031){ref-type="ref"}, [32](#lio2288-bib-0032){ref-type="ref"} And in the future, an improved understanding of CI genetics will lay the groundwork for tailor‐made CIs and implantable devices that provide molecular therapies.

MOLECULAR PHYSIOLOGY OF HEARING AND DEAFNESS, A CI PERSPECTIVE {#lio2288-sec-0005}
==============================================================

Over the past 30 years, our understanding of genetics of deafness has greatly expanded our view of the molecular physiology of the auditory system. Deafness is extremely genetically heterogeneous. Unlike a disease like cystic fibrosis, where the vast majority of cases are due to variants affecting a single gene, there are more than 110 known deafness genes with more than 7,000 known deafness causing variations (<http://deafnessvariationdatabase.org>; <http://hereditaryhearingloss.org>). Genetic variants have been identified that cause deafness by affecting each component of hearing from sensory transduction to transmission of sound to the brain. This extreme genetic heterogeneity underscores the fragility, complexity, and importance of human hearing.

Approximately 80% of congenital hearing loss in the United States is due to a genetic cause and genetics are likely to contribute a significant partition of postlingual and adult onset hearing loss as well.[33](#lio2288-bib-0033){ref-type="ref"} Understanding these genes and how, when mutated, they cause deafness, provides a high resolution understanding of the molecular mechanisms of CI outcomes. We will briefly review CI outcomes for genes affecting the sensory partition of the peripheral auditory system and then focus individually on each of the genes known to cause ANSD by affecting the synapse or the spiral ganglion itself. Converging data supports the hypothesis that genetic mutations negatively affecting the spiral ganglion itself lead to worse CI outcomes, presumably through worsened spiral ganglion health.

GENETIC LESIONS TO THE SENSORY (COCHLEAR) PARTITION {#lio2288-sec-0006}
===================================================

Defects in any of the sensory components of the organ of Corti including inner hair cells, outer hair cells, the tectorial membrane, supporting cells, or cells of the stria vascularis can lead to deafness. Deafness due to a mutation in *GJB2* was first described in 1997, and since that time has been shown to be one of the most frequent causes of congenital severe‐to‐profound hearing loss.[34](#lio2288-bib-0034){ref-type="ref"} The *GJB2* gene encodes connexin 26, which forms a pore that allows the flow of K+ and maintains the ionic gradient of the scala media and allows the mechanotransduction of sound. Mutations in *GJB2* have been shown in multiple studies to be associated with excellent CI outcomes.[35](#lio2288-bib-0035){ref-type="ref"}, [36](#lio2288-bib-0036){ref-type="ref"}, [37](#lio2288-bib-0037){ref-type="ref"}, [38](#lio2288-bib-0038){ref-type="ref"} Similarly, good CI outcomes have been reported in individuals with other genetic lesions affecting the sensory apparatus including mutations in genes that affect the cells of the stria vascularis (*SLC26A4* [38](#lio2288-bib-0038){ref-type="ref"}), the tip‐links of the stereocilia of the inner hair cells (*CDH23* [39](#lio2288-bib-0039){ref-type="ref"}, [40](#lio2288-bib-0040){ref-type="ref"}), the unconventional myosin motor proteins of the hair cells (*MYO7A* [40](#lio2288-bib-0040){ref-type="ref"}), and the stereocilia structure itself (*LOXHD1* [41](#lio2288-bib-0041){ref-type="ref"}), among others. One large study of 173 individuals who underwent cochlear implantation showed that any mutation in a deafness‐causing gene affecting the organ of Corti was associated with good CI outcomes.[42](#lio2288-bib-0042){ref-type="ref"} Our group performed a statistical analysis of 155 individuals who underwent cochlear implantation and found that those patients with deafness due to mutations in the sensory partition of the peripheral auditory system had postoperative CI outcomes significantly better than other groups.[43](#lio2288-bib-0043){ref-type="ref"} In summary, for patients with identifiable genetic site of lesion in the sensory partition of the peripheral auditory system, CI outcomes are expected to be excellent as the CI bypasses the defective partition of the auditory system.

GENETIC LESIONS TO THE SYNAPSE {#lio2288-sec-0007}
==============================

Auditory synaptopathy is the term used for ANSD due to a defective or poorly functioning synapse. Persons with hearing loss caused by a genetic mutation affecting the synapse would be expected to have normal OAE response but an altered ABR, as in other forms of ANSD. The auditory synapse is bypassed by the CI and so we would hypothesize that individuals with a defect in the synapse would have good performance with a CI (Fig. [1](#lio2288-fig-0001){ref-type="fig"}).

Auditory synaptopathies can be distinguished from auditory neuropathies by ECochG: individuals with synaptopathy appear to have enhanced adaptation to frequency specific tones whereas those with neuropathy had abnormal low frequency adaptation.[44](#lio2288-bib-0044){ref-type="ref"} The inner hair cell ribbon synapse is unique to the auditory system. Therefore, genetic auditory synaptopathies typically only cause deafness; in contrast, genetic neuropathies frequently affect other peripheral neurons as well leading to syndromic phenotypes. Auditory synaptopathies are rare and so studying these genetic lesions is of utmost importance to improving our understanding the human auditory system and CI outcomes.

Calcium influx at the base of the inner hair cell near the ribbon synapse is mediated via the Cav1.3L‐type Ca2+ channel, encoded by the *CACNA1D* gene. Otoferlin, encoded by the gene *OTOF*, is one protein responsible for regulating exocytosis of glutamatergic vesicles at the presynaptic site. The vesicular glutamate transporter type 3 (*VGLUT3* gene) is responsible for glutamate uptake at the postsynaptic site. Synaptopathies can therefore be classified specifically based on the site of lesion to the synapse: pre‐ or postsynaptic. This high resolution classification will assist with analysis of electrophysiologic data in these individuals. Specific genetic lesions that cause pre‐ or postsynaptic auditory synaptopathy will be described in detail below and are summarized in Table [1](#lio2288-tbl-0001){ref-type="table"}.

###### 

Genes identified to cause auditory neuropathy spectrum disorder including auditory synaptopathy and neuropathy.

  Functional Component                                Site of Lesion                                                          Gene                                                                                    Protein                                                                            Function                                                                    Phenotype                                                                         Total Reported Deafness‐Causing Mutations                      CI Outcomes                               CI Outcomes References
  --------------------------------------------------- ----------------------------------------------------------------------- --------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- --------------------------------------------------------------------------- ------------------------------------------------------------- ---------------------------------------------------------------------------------- ----------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Synapse                                             Presynaptic---inner hair cell                                           *OTOF*                                                                                  Otoferlin                                                                          Calcium sensor involved in exocytosis of synaptic vesicles                  Autosomal recessive NSHL and temperature‐sensitive deafness                                          113                                         Good                                      [42](#lio2288-bib-0042){ref-type="ref"}, [45](#lio2288-bib-0045){ref-type="ref"}, [46](#lio2288-bib-0046){ref-type="ref"}, [47](#lio2288-bib-0047){ref-type="ref"}, [48](#lio2288-bib-0048){ref-type="ref"}
  *CACNA1D* [\*](#lio2288-note-0003){ref-type="fn"}   Calcium voltage‐gated channel subunit alpha1 D (Cav1.3)                 Calcium influx at the presynaptic site                                                  Sinoatrial node dysfunction and deafness syndrome (SANND)                          1                                                                           ---                                                                                                  ---                                                                                   
  *CABP2* [\*](#lio2288-note-0003){ref-type="fn"}     Calcium binding protein 2                                               Interaction with calcium channels to alter voltage dependence at the presynaptic site   Autosomal recessive NSHL                                                           3                                                                           ---                                                                                                  ---                                                                                   
  *SLC17A8*                                           VGLUT3: vesicular glutamate transporter 3                               Involved in presynaptic vesicular glutamate uptake and release                          Autosomal dominant NSHL                                                            1                                                                           Good                                                                               [43](#lio2288-bib-0043){ref-type="ref"}                                                                 
  Postsynaptic---spiral ganglion                      *DIAPH3*                                                                Diaphanous formin 3                                                                     Involved in spiral ganglion terminal dendrite contact with inner hair cells        Autosomal dominant NSHL                                                     1                                                                                                    Good                                        [49](#lio2288-bib-0049){ref-type="ref"}   
  *OPA1*                                              Mitochondrial dynamin related GTPase protein                            Involved in spiral ganglion terminal dendrite growth                                    DOA, or DOA and auditory neuropathy (DOA+)                                         6                                                                           Good                                                           [24](#lio2288-bib-0024){ref-type="ref"}, [50](#lio2288-bib-0050){ref-type="ref"}                                            
  *ROR1*                                              Receptor tyrosine kinase‐like orphan receptor                           Modulates spiral ganglion terminal dendrite growth                                      Common cavity malformation and auditory neuropathy, autosomal recessive            1                                                                           Good                                                                               [51](#lio2288-bib-0051){ref-type="ref"}                                                                 
  *ATP1A3*                                            Alpha‐3 catalytic subunit of the Na+/K+ ATPase transmembrane ion pump   Maintains resting membrane potentials in spiral ganglion terminal dendrites             NSHL and CAPOS syndrome                                                            1                                                                           Good                                                                               [52](#lio2288-bib-0052){ref-type="ref"}                                                                 
  Auditory nerve                                      Spiral ganglion cell bodies and proximal axons                          *TIMM8A*                                                                                Translocase of inner mitochondrial membrane 8A                                     Defective mitochondrial transport leads to degeneration of auditory nerve   Mohr‐Tranebjaerg syndrome (DDON)                                                                      6                                          Poor                                      [53](#lio2288-bib-0053){ref-type="ref"}, [54](#lio2288-bib-0054){ref-type="ref"}
  *AIFM1*                                             Apoptosis‐inducing factor 1                                             Oxidative phosphorylation and respiratory chain                                         X‐linked auditory neuropathy and Cowchock syndrome                                 11                                                                          ---                                                                                                                                                                                        
  *NARS2*                                             Mitochondrial asparagine‐tRNA ligase                                    Mitochondrial respiratory chain, oxidative phosphorylation                              Autosomal recessive NSHL; Leigh syndrome (progressive neurodegenerative disease)   2                                                                           ---                                                                                                                                                                                        
  *MPZ*, *PMP22*                                      ---                                                                     ---                                                                                     Charcot‐Marie‐Tooth disease, hereditary sensory and motor neuropathy               ---                                                                         Poor                                                                               [54](#lio2288-bib-0054){ref-type="ref"}                                                                 

There is no current clinical evidence or data from animal models implicating this gene as a cause of ANSD, but in vitro analysis supports the hypothesis that this gene causes ANSD.

ANSD = auditory neuropathy spectrum disorder; CAPOS = cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss; CI = cochlear implant; DDON = deafness‐dystonia‐optic neuropathy; DOA = dominant optic atrophy; NSHL = non‐syndromic hearing loss.

###### 

Genes hypothesized to be involved in synaptic or spiral ganglion function but with unclear function.

  Gene        Diagnosis                                               Deafness Onset                               Deafness Severity                                                   Protein                           Protein Expression                                                  Protein Function                                                            CI Outcomes
  ----------- ------------------------------------------------------- -------------------------------------------- ------------------------------------------------------------------- --------------------------------- ------------------------------------------------------------------- --------------------------------------------------------------------------- ------------------------------------------------
  *TMPRSS3*   Autosomal recessive NSHL                                Prelingual (DFNB10) or postlingual (DFNB8)   Severe to profound (DFNB10) or progressive high frequency (DFNB8)   Transmembrane serine protease 3   Inner hair cells, outer hair cells, type II spiral ganglion cells   Unknown                                                                     Variable
  *TBC1D24*   Autosomal recessive or dominant NSHL; epilepsy; DOORS   Congenital or postlingual                    Severe to profound or progressive                                   TBC1D24 protein                   Inner hair cells outer hair cells, spiral ganglion neurons          Involved in neural maturation in the cortex                                 Unknown
  *DFNB59*    Autosomal recessive NSHL                                Congenital                                   Severe to profound                                                  Pejvakin                          Inner hair cells, outer hair cells, spiral ganglion cells           Functions in peroxisomes which protect cells from reactive oxygen species   Unknown[\*](#lio2288-note-0005){ref-type="fn"}

One case‐control study found that a polymorphism in *DFNB59*, p.G292R, was associated with worse cochlear implant outcomes.[104](#lio2288-bib-0104){ref-type="ref"}

CI = cochlear implant; DOORS = deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures; NSHL = non‐syndromic hearing loss.

*OTOF---Presynaptic Synaptopathy* {#lio2288-sec-0008}
---------------------------------

Mutations in the gene *OTOF* were first identified as a cause of autosomal recessive nonsyndromic deafness, DFNB9, nearly 20 years ago.[55](#lio2288-bib-0055){ref-type="ref"} DFNB9 deafness is severe‐to‐profound congenital or prelingual deafness characterized by present OAEs and abnormal ABR. *OTOF* was the first identified genetic cause of ANSD. In addition to nonsyndromic hearing loss (NSHL), mutations in *OTOF* can also cause temperature‐sensitive deafness whereby an elevation in body temperature can severely worsen hearing loss, in particular word understanding and tinnitus, but this then returns to close to normal hearing on body cooling.[56](#lio2288-bib-0056){ref-type="ref"} Similar mutations in *OTOF* may lead to disparate audiologic outcomes, as evidenced by one study of two siblings with ANSD and the same *OTOF* mutation but significantly different speech reception scores, electrically evoked potentials, and CI outcomes.[57](#lio2288-bib-0057){ref-type="ref"}

The otoferlin protein acts as a calcium sensor, which is required for the final stages of exocytosis of the glutamatergic vesicles in inner hair cells at the ribbon synapse, but the exact mechanism by which it performs this function is unknown.[58](#lio2288-bib-0058){ref-type="ref"} *Otof* knockout mice are able to complete all stages of exocytosis aside from the final step, glutamate release. Detailed studies on humans with *OTOF* mutations show that these individuals have progressive auditory fatigue, which likely represents a failure of the normally indefatigable auditory synapse.[44](#lio2288-bib-0044){ref-type="ref"} These results show the mechanisms by which genetic alterations to *OTOF* can affect the temporal representation of auditory stimuli and cause auditory synaptopathy.

To date, a total of 113 deafness‐causing mutations in *OTOF* have been reported which encompass missense as well as loss of function changes (<http://deafnessvariationdatabse.org>). *OTOF* mutations are particularly prominent in the Spanish population where up to 8% of autosomal recessive nonsyndromic hearing loss is due to *OTOF* mutations likely due to a founder effect.[45](#lio2288-bib-0045){ref-type="ref"} In a large multiethnic population of 1,119 individuals with hearing loss, mutations in *OTOF* accounted for 2.4% of diagnoses, the 12th most common gene causing deafness in this cohort.[34](#lio2288-bib-0034){ref-type="ref"}

Available data from multiple case‐series show that CI outcomes for individuals with *OTOF* are excellent and typically on par with individuals with genetic mutations affecting the sensory partition.[42](#lio2288-bib-0042){ref-type="ref"}, [45](#lio2288-bib-0045){ref-type="ref"}, [46](#lio2288-bib-0046){ref-type="ref"}, [47](#lio2288-bib-0047){ref-type="ref"}, [48](#lio2288-bib-0048){ref-type="ref"} A recent review identified 32 different patients from 11 published studies with different *OTOF* mutations, all of whom had good or excellent CI outcomes.[59](#lio2288-bib-0059){ref-type="ref"} The data from *OTOF* are the strongest to confirm that auditory synaptopathies are bypassed by a CI and therefore have good CI outcomes.

*CACNA1D---Presynaptic Synaptopathy* {#lio2288-sec-0009}
------------------------------------

*CACNA1D* encodes the voltage‐gated calcium channel subunit alpha1 D, also known as Cav1.3. Mutations in the gene *CACNA1D* cause a syndromic form of hearing loss called sinoatrial node dysfunction and deafness syndrome (SANND syndrome).[60](#lio2288-bib-0060){ref-type="ref"} The affected calcium channel, Cav1.3, is expressed in inner and outer hair cells, cardiomyocytes, neuroendocrine cells, and neurons resulting in the syndromic deafness when loss of function mutations occur. The gene encodes for part of the pore‐forming subunit of the calcium channel. Loss of function mutations of *CACNA1D* lead to impaired synaptic transmission at the ribbon synapse in knockout mice.[61](#lio2288-bib-0061){ref-type="ref"}, [62](#lio2288-bib-0062){ref-type="ref"}

Only one mutation found in two Pakistani families has been identified to cause SANDD syndrome. Deafness caused by this mutation is congenital and severe to profound and accompanied by bradycardia. No evaluation of auditory neuropathy was provided but based on molecular characterization, these patients would be expected to display characteristics of ANSD. Further information on CI outcomes is pending but we would hypothesize that because this is a synaptopathy patients would have an excellent CI outcome.

*CABP2---Presynaptic Synaptopathy* {#lio2288-sec-0010}
----------------------------------

Calcium binding proteins interact with calcium channels to alter the voltage‐dependence of the voltage‐gated pore at the presynaptic site at the base of hair cells. Mutations in *CAPB2* cause autosomal recessive nonsyndromic hearing loss at the DFNB93 locus.[63](#lio2288-bib-0063){ref-type="ref"} A lack of Ca2+ influx leads to impaired vesicular release of glutamate and an auditory synaptopathy. The original reported mutation causing deafness was identified in an Iraqi family with flat or cookie‐bite moderate to severe prelingual onset with Marfanoid features but no other syndromic features.[63](#lio2288-bib-0063){ref-type="ref"} A total of three deafness causing mutations in *CABP2* have been published but there have been no reported CI outcomes.

*SLC17A8---Presynaptic Synaptopathy* {#lio2288-sec-0011}
------------------------------------

Mutations in the gene *SLC17A8* cause autosomal dominant nonsyndromic hearing loss at the DFNA25 locus.[64](#lio2288-bib-0064){ref-type="ref"} Affected individuals have progressive high‐frequency sensorineural hearing loss. There are only three reported pathogenic mutations in SLC17A8 causing nonsyndromic hearing loss including the original report and two in Korean families.[64](#lio2288-bib-0064){ref-type="ref"}, [65](#lio2288-bib-0065){ref-type="ref"}, [66](#lio2288-bib-0066){ref-type="ref"} There are no reports of features of auditory neuropathy in these families but detailed electrophysiologic studies for these patients have not been published.

*SLC17A8* encodes for VGLUT3, the vesicular glutamate transporter 3 protein. Mice with mutations in *Slc17a*8 have been shown to have auditory neuropathy.[67](#lio2288-bib-0067){ref-type="ref"} Hearing loss in *Slc17a8* knockout mice is due to the lack of glutamate exocytosis by inner hair cells and therefore a lack of synaptic transmission at the IHC‐SG terminal dendrite synapse.[64](#lio2288-bib-0064){ref-type="ref"}, [67](#lio2288-bib-0067){ref-type="ref"} Importantly, viral mediated transfer of the *Slc17a8* gene to IHCs rescues the hearing loss in these mice, representing an avenue for future gene therapy in humans.[68](#lio2288-bib-0068){ref-type="ref"}

One study that included one patient with *SLC17A8* deafness showed a relatively good CI outcome.[43](#lio2288-bib-0043){ref-type="ref"} This is consistent with the molecular physiology of this protein directly affecting the presynaptic site. Further studies are needed to confirm this finding.

*DIAPH3---Postsynaptic Synaptopathy* {#lio2288-sec-0012}
------------------------------------

Mutations in *DIAPH3* cause nonsyndromic auditory neuropathy via a postsynaptic lesion. To date, there is only a single reported deafness‐causing mutation.[69](#lio2288-bib-0069){ref-type="ref"} Affected individuals have postlingual onset progressive hearing loss with initially retained OAEs that diminish over time.[49](#lio2288-bib-0049){ref-type="ref"} Electrophysiologic studies localized the lesion to the distal neurite, synapse, or inner hair cell.[49](#lio2288-bib-0049){ref-type="ref"} The *DIAPH3* gene encodes the diaphanous formin 3 gene, overexpression of which appears to affect distal neurite contact with inner hair cells.[69](#lio2288-bib-0069){ref-type="ref"} Three individuals with *DIAPH3* deafness have received CIs and had good outcomes, as could be hypothesized based on the site of lesion at the distal neurite.[49](#lio2288-bib-0049){ref-type="ref"}

*OPA1---Postsynaptic Synaptopathy* {#lio2288-sec-0013}
----------------------------------

Mutations in the gene *OPA1* cause dominant optic atrophy (DOA) or syndromic dominant optic atrophy (DOA+). DOA+ is characterized by optic atrophy and auditory neuropathy. Mutations that cause haploinsufficiency, or lack of a full component of the optic atrophy 1 protein, result in DOA whereas missense mutations that act via a dominant negative mechanism to inhibit the activity of the normal remaining protein cause DOA+.[70](#lio2288-bib-0070){ref-type="ref"} There are six reported DOA+ mutations, but the most commonly identified mutation is p.Arg445His.

The *OPA1* gene encodes for the mitochondrial dynamin‐related GTPase protein which is crucial for mitochondrial functioning. It is hypothesized that mutations causing DOA+ result in degeneration of the terminal axons of spiral ganglion neurons and thus cause a postsynaptic auditory synaptopathy.[70](#lio2288-bib-0070){ref-type="ref"} Individuals with DOA+ have preserved OAEs but abnormal ABRs. The hearing loss is moderate to severe and variable in which frequencies are affected predominately, even within the same family.[50](#lio2288-bib-0050){ref-type="ref"}, [70](#lio2288-bib-0070){ref-type="ref"} Several individuals with DOA+ who received CIs were found to have good outcomes which is consistent with the hypothesized site of lesion at the peripheral axons of the spiral ganglion, preventing appropriate synaptic transmission, yet the neuronal somata are presumably preserved and responsive to electrical stimulation.[70](#lio2288-bib-0070){ref-type="ref"}

*ROR1---Postsynaptic Synaptopathy* {#lio2288-sec-0014}
----------------------------------

*ROR1* encodes for the receptor tyrosine kinase‐like orphan receptor, a protein which is important for neurite outgrowth. Two siblings from a Turkish family with cochlear common cavity malformation, moderate to severe downsloping SNHL, and normal OAE response, indicative of auditory neuropathy were found to have a mutation in the gene *ROR1*.[51](#lio2288-bib-0051){ref-type="ref"} This gene encodes for receptor tyrosine kinase‐like orphan receptor 1, a transmembrane protein involved in cell signaling via the Wnt pathway. Knockout mice showed multiple other defects including urogenital and skeletal abnormalities as well as growth retardation, but also showed common cavity malformation and deafness. Examination of the cochlea in knockout Ror1 mice showed a lack of innervation of the inner hair cells by peripheral axons of spiral ganglion neurons as well as aberrant growth of spiral ganglion neuron axons toward outer hair cells. Therefore, mutations in *ROR1* cause an auditory synaptopathy affecting the postsynaptic site.[51](#lio2288-bib-0051){ref-type="ref"} There is only one reported deafness‐causing mutation in *ROR1*. One of the two affected individuals received a CI with good outcomes.[51](#lio2288-bib-0051){ref-type="ref"}

*ATP1A3---Postsynaptic Synaptopathy* {#lio2288-sec-0015}
------------------------------------

Mutations in *ATP1A3* cause CAPOS syndrome (cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss) as well as NSHL without any other neurologic features.[52](#lio2288-bib-0052){ref-type="ref"} Detailed audiometric analysis of two individuals with mutations in *ATP1A3* showed auditory synaptopathy likely affecting the postsynaptic site.[52](#lio2288-bib-0052){ref-type="ref"} These two patients both showed excellent postoperative outcomes after cochlear implantation. *ATP1A3* encodes the α3 catalytic subunit of Na+/K+ ATPase (adenosine triphosphotase), which is a membrane‐bound transporter that uses ATP to maintain a resting transmembrane potential in nerve dendritic terminals. This transporter was shown to be expressed abundantly in the peripheral axons of spiral ganglion neurons in rats.[71](#lio2288-bib-0071){ref-type="ref"} The exact mechanism(s) whereby mutations in *ATP1A3* cause auditory synaptopathy remain unknown, but it is hypothesized that EPSPs are affected due to altered resting membrane potential.

GENETIC LESIONS AFFECTING THE SPIRAL GANGLION AND AUDITORY NERVE {#lio2288-sec-0016}
================================================================

Spiral ganglion neurons are bipolar, with cell bodies located in the modiolus of the cochlea, peripheral axons running through the spiral limbus toward the row of inner hair cells of the cochlea, and proximal axons synapsing at the midbrain in a tonotopical organization.[72](#lio2288-bib-0072){ref-type="ref"} Each spiral ganglion neuron is frequency‐tuned based, in part, on the inner hair cell from which it receives afferent information. There are multiple spiral ganglion peripheral fibers synapsing with each inner hair cell. The axons of spiral ganglion neurons are ensheathed by myelinating Schwann cells along their distal, peripheral axons projecting to the organ of Corti and the early partition of the central projections. As the proximal, central axons project to the brainstem, there is a transition from peripheral myelin by Schwann cells to central myelin by oligodendrocytes.[73](#lio2288-bib-0073){ref-type="ref"} In response to glutamatergic stimulation at the synapse, postsynaptic excitatory potentials at the peripheral axon lead to Na+ influx via a large number of channels in a graded fashion that allows for precise temporal coding of acoustic stimuli.

Genetic lesions that affect the signal transmission to the brain lead to a loss of temporal precision and dyssynchrony, or a degraded potential and altered perception and/or understanding of sound, either of which cause deafness through auditory neuropathy. There are several genes identified that cause auditory neuropathy and these are detailed below. A genetic lesion that specifically affects the auditory nerve would be not be bypassed by a CI and could theoretically affect CI outcomes. Genes that, when mutated, cause auditory neuropathy often lead to syndromic forms of hearing loss particularly hereditary neuropathies, as other peripheral neurons are often affected in addition to the spiral ganglion.

*TIMM8A* {#lio2288-sec-0017}
--------

Mohr‐Tranaebjaerg Syndrome, also known as deafness‐dystonia‐optic neuropathy (DDON) syndrome is a progressive neurodegenerative genetic disorder characterized by early childhood onset auditory neuropathy, dystonia and ataxia that present in the second decade, decreased visual acuity starting in the third decade, and dementia starting in the fifth decade.[74](#lio2288-bib-0074){ref-type="ref"} Each of these clinical findings is progressive. There are also psychiatric features such as paranoia. Mutations in *TIMM8A* cause DDON in an X‐linked recessive inheritance pattern.

Pathologic evaluation of human temporal bones in patients with DDON shows near total loss of cochlear neuronal cells and severe loss of vestibular neurons in four subjects examined. The disease process is therefore characterized as postnatal progressive degeneration of neurons, including cochlear, vestibular, and optic neurons.[75](#lio2288-bib-0075){ref-type="ref"} DDON therefore represents the prototypical auditory neuropathy. There are 12 reported pathologic mutations in the *TIMM8A* that cause DDON.

One report of a patient with DDON implanted with a CI at age 4 showed that after 2 years, he had only marginal performance with the CI even at high current levels.[53](#lio2288-bib-0053){ref-type="ref"} In patients for whom cochlear implantation has failed or for whom cochlear implantation is not feasible due to cochlear nerve aplasia or hypoplasia, auditory brainstem implantation is an option; one study of DDON patients showed reasonable outcome after removal of CIs and replacement with auditory brainstem implants.[54](#lio2288-bib-0054){ref-type="ref"}

*AIFM1* {#lio2288-sec-0018}
-------

Mutations in the gene *AIFM1* cause X‐linked auditory neuropathy as well as Cowchock syndrome, a progressive neuromuscular disorder associated with deafness and cognitive impairment. Individuals with isolated X‐linked auditory neuropathy also show a delayed onset peripheral sensory neuropathy presenting as extremity numbness, unsteadiness, and areflexia.[76](#lio2288-bib-0076){ref-type="ref"} To date, there are 11 reported deafness‐causing mutations.

*AIFM1* encodes apoptosis‐inducing factor 1, a flavoprotein located in the mitochondrial intermembrane space and localized to inner and outer hair cells as well as spiral ganglion neurons. The AIFM1 protein plays a role in oxidative phosphorylation, redox control, and respiratory chain activity in healthy cells. Several patients with these mutations have been shown to have cochlear nerve hypoplasia which appears to be delayed in onset (not congenital).[76](#lio2288-bib-0076){ref-type="ref"} There are no reports of cochlear implantation in these subjects, but they would be expected to have poor outcomes, particularly if there is cochlear nerve deficiency.

*NARS2* {#lio2288-sec-0019}
-------

Mutations in *NARS2* cause autosomal recessive nonsyndromic auditory neuropathy as well Leigh Syndrome, an early‐onset progressive neurodegenerative disorder affecting the central nervous system (CNS) with symptoms dependent on involved areas of the CNS.[77](#lio2288-bib-0077){ref-type="ref"} NARS2 encodes the mitochondrial asparagine‐tRNA ligase protein which is involved in energy metabolism including the respiratory chain complexes. In individuals with *NARS2* mutations and Leigh syndrome, initial evaluation showed absent ABRs but present CM, however by 11 weeks OAEs were absent.[77](#lio2288-bib-0077){ref-type="ref"} There is only one family reported with isolated deafness and NARS2 mutations. This family had congenital severe to profound SNHL but detailed electrophysiologic information including ABR and OAE was not available.[77](#lio2288-bib-0077){ref-type="ref"}

The NARS2 protein is expressed in the spiral ganglion as well as several cells of the organ of Corti. It is hypothesized that deafness is due to cellular damage that may affect spiral ganglion neurons first prior to affecting hair cells.[77](#lio2288-bib-0077){ref-type="ref"}

*Hereditary Demyelinating Neuropathies* {#lio2288-sec-0020}
---------------------------------------

Auditory neuropathy is a common finding in Charcot‐Marie‐Tooth disease (CMT). CMT is the most common inherited neurologic disorder, affecting 1 in 2,500 people and characterized by progressive motor and sensory neuropathy. There are several types of CMT which vary based on severity, involved nerves, and inheritance, and to date more than 80 genes have been identified to cause CMT.[78](#lio2288-bib-0078){ref-type="ref"} Two genes in particular, *MPZ* and *PMP22*, have been associated with CMT involving auditory neuropathy. Temporal bone histology of patients with autosomal dominant ANSD and demyelinating CMT showed normal cochlear hair cells but a marked degeneration of spiral ganglion neurons.[79](#lio2288-bib-0079){ref-type="ref"}

One report of an individual with CMT who underwent cochlear implantation showed postoperative speech discrimination score of 54%, indicating a relatively poor result but that that some improvement in possible even in the face of likely auditory nerve degeneration.[80](#lio2288-bib-0080){ref-type="ref"} Other hereditary progressive motor and sensory neuropathies with auditory neuropathy such as Friedreich ataxia are likely to have similar lesions within the spiral ganglion.[81](#lio2288-bib-0081){ref-type="ref"} Cochlear implantation for these individuals will likely have less‐than ideal postoperative outcomes, but can still be offered as a treatment option for deafness.[82](#lio2288-bib-0082){ref-type="ref"}

GENES WITH POSSIBLE EFFECTS ON THE AUDITORY SYNAPSE OR SPIRAL GANGLION {#lio2288-sec-0021}
======================================================================

*TMPRSS3* {#lio2288-sec-0022}
---------

Mutations in the gene *TMPRSS3* cause two different types of autosomal recessive NSHL: congenital severe‐to‐profound deafness (DFNB10), and postlingual progressive deafness (DFNB8).[83](#lio2288-bib-0083){ref-type="ref"}, [84](#lio2288-bib-0084){ref-type="ref"}, [85](#lio2288-bib-0085){ref-type="ref"} The type of deafness depends on the type of mutation, and there are clear genotype‐phenotype correlations between more damaging mutations with early onset and more severe hearing loss.[86](#lio2288-bib-0086){ref-type="ref"}, [87](#lio2288-bib-0087){ref-type="ref"} To date, there are 41 reported deafness‐causing mutations in *TMPRSS3*. The function of the protein encoded by *TMPRSS3*, transmembrane serine protease 3, is unknown. However, multiple studies have shown the protein to be expressed in inner and outer hair cells as well as the spiral ganglion, including in dissected human temporal bones.[88](#lio2288-bib-0088){ref-type="ref"}, [89](#lio2288-bib-0089){ref-type="ref"}, [90](#lio2288-bib-0090){ref-type="ref"}, [91](#lio2288-bib-0091){ref-type="ref"} A recent study showed that *TMPRSS3* is expressed highly in type II spiral ganglion neurons in mice.[92](#lio2288-bib-0092){ref-type="ref"} *TMPRSS3* function is required for hair cell survival in mice[90](#lio2288-bib-0090){ref-type="ref"}and also spiral ganglion neuron survival in vitro.[93](#lio2288-bib-0093){ref-type="ref"}

There are no reports that *TMPRSS3* mutations cause ANSD. However, DFNB8 mutations in *TMPRSS3* are the most common cause of genetic deafness in a large cohort of CI users with postlingual onset deafness.[43](#lio2288-bib-0043){ref-type="ref"} Therefore, understanding the role of *TMPRSS3* in the peripheral auditory system is critical. CI outcomes with *TMPRSS3* mutations have been variable, with some studies showing good outcomes[86](#lio2288-bib-0086){ref-type="ref"}, [94](#lio2288-bib-0094){ref-type="ref"} while others have shown below‐average outcomes.[43](#lio2288-bib-0043){ref-type="ref"}, [95](#lio2288-bib-0095){ref-type="ref"}, [96](#lio2288-bib-0096){ref-type="ref"} Understanding deafness due to *TMPRSS3* mutations is complicated by multiple phenotypes which may indicate multiple molecular lesions. One hypothesis is that more severe *TMPRSS3* mutations may predominantly affect the hair cells, while more mild mutations may primarily affect the spiral ganglion. Importantly a recent report on patients with *TMPRSS3* mutations and hearing preservation CIs demonstrated disrupted neural responses and relatively well‐preserved cochlear microphonic responses.[30](#lio2288-bib-0030){ref-type="ref"} Further research is needed to determine the exact mechanisms by which mutations in *TMPRSS3* cause deafness and how these mechanisms may affect CI outcomes.

*TBC1D24* {#lio2288-sec-0023}
---------

Mutations in the gene *TBC1D24* cause nonsyndromic hearing loss, genetic epilepsy, and Deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures (DOORS) syndrome (Table [2](#lio2288-tbl-0002){ref-type="table"}). Mutations in *TBC1D24* have been shown to cause both congenital severe to profound autosomal recessive nonsyndromic SNHL[97](#lio2288-bib-0097){ref-type="ref"} as well as autosomal dominant progressive nonsyndromic SNHL.[98](#lio2288-bib-0098){ref-type="ref"} There are 25 reported mutations in *TBC1D24* including nonsyndromic hearing loss, DOORS syndrome, and epilepsy. None of the affected individuals from these families had epilepsy.

The *TBC1D24* gene encodes the Tre2‐Bub2‐Cdc16 (TBC) domain‐containing RAB‐specific GTPase‐activating protein 24 which is expressed in inner and outer hair cells as well as in the spiral ganglion.[97](#lio2288-bib-0097){ref-type="ref"}, [98](#lio2288-bib-0098){ref-type="ref"} This protein has been shown to be crucial for distal neurite outgrowth and maturation of cortical neurons.[99](#lio2288-bib-0099){ref-type="ref"} Therefore, mutations in *TBC1D24* would be hypothesized to cause a postsynaptic auditory synaptopathy.

Whether mutations in *TBC1D24* cause ANSD is still unknown as detailed physiologic analysis of the affected families including OAE and ECochG are not available. The *TBC1D24* gene is a good candidate for auditory neuropathy given its involvement in the CNS (epilepsy) and expression in the spiral ganglion, but further research is needed to determine the function of the *TBC1D24* gene in the human auditory system.

*DFNB59* {#lio2288-sec-0024}
--------

Mutations in the gene *DFNB59* were identified as the second genetic cause of auditory neuropathy (Table [2](#lio2288-tbl-0002){ref-type="table"}).[100](#lio2288-bib-0100){ref-type="ref"} Both affected individuals and knock‐in mice showed preserved OAEs and altered ABRs. However, a second study showed that affected individuals had no signs of auditory neuropathy with a lack of OAEs and CM,[101](#lio2288-bib-0101){ref-type="ref"} and a second Dfnb59 mutant mouse lacked OAEs.[102](#lio2288-bib-0102){ref-type="ref"} The protein encoded by *DFNB59*, pejvakin, plays a role in formation of peroxisomes which protect cells from damage during antioxidant response.[103](#lio2288-bib-0103){ref-type="ref"} Pejvakin is expressed in the inner and outer hair cells as well as spiral ganglion neurons.[103](#lio2288-bib-0103){ref-type="ref"} The exact role of DFNB59 in the peripheral auditory system is unclear. To date, there are 16 reported deafness‐causing mutations in this gene, two of which have been reported to cause auditory neuropathy.[100](#lio2288-bib-0100){ref-type="ref"} There are no reports of CI outcomes with individuals with deafness causing by *DFNB59* mutations. However, one case‐control study showed that a polymorphism in the *DFNB59* gene, p.G292R (rs79399438) which is present in 2.9% of individuals, is associated with worse CI outcomes.[104](#lio2288-bib-0104){ref-type="ref"} Further research is clearly needed to better understand the role of pejvakin in the auditory system including whether it truly causes an auditory neuropathy phenotype.

CONCLUSIONS {#lio2288-sec-0025}
===========

Aside from the binary absence or presence of a cochlear nerve, it is becoming apparent that all CI candidates will have a broad spectrum of auditory nerve functional ability. Assessment of the "health" of the spiral ganglion and auditory nerve has become a key focus of predicting CI outcomes.[15](#lio2288-bib-0015){ref-type="ref"}, [24](#lio2288-bib-0024){ref-type="ref"}, [30](#lio2288-bib-0030){ref-type="ref"}

Many studies have attempted to determine if cochlear implantation will benefit individuals with auditory neuropathy. Initially, researchers felt that auditory neuropathy was a contraindication to implantation.[19](#lio2288-bib-0019){ref-type="ref"} However, there were some initial reports of success of cochlear implantation in these patients.[105](#lio2288-bib-0105){ref-type="ref"}, [106](#lio2288-bib-0106){ref-type="ref"} Subsequently, several studies have found worse CI outcomes in patients with ANSD; yet despite poorer outcomes compared to typical CI recipients, patients with ANSD often still benefit from cochlear implantation.[21](#lio2288-bib-0021){ref-type="ref"}, [107](#lio2288-bib-0107){ref-type="ref"} Other studies, including a systematic review, have shown more variable outcomes in patients with ANSD following cochlear implantation.[108](#lio2288-bib-0108){ref-type="ref"}, [109](#lio2288-bib-0109){ref-type="ref"} A primary flaw in studies of patients with ANSD and CIs is that the studies do not precisely define the site lesion involved in the individuals studied. The studied groups are composed of an unknown number of individuals with neuropathy or synaptopathy which, as described here, are expected to have different CI outcomes.

As described in this review, the precise site of lesion causing neuropathy can help to determine at least a portion of expected postoperative outcomes. Preferably, a molecular diagnosis along with physiologic data from ECochG to determine the exact site of lesion should be available for each individual to be studied. Only then we can accurately study postoperative CI outcomes in individuals with ANSD. An ideal study would compare large numbers of individuals with specific genetic forms of deafness, controlled for clinical variables including duration of deafness, time of implantation, socioeconomic status, and type of CI. Due to the extreme genetic heterogeneity of deafness, this will require a large number of patients to obtain groups large enough for comparison.

The data are currently limited to a small number of patients with variable tests used for diagnosis and evaluation of outcome. Accordingly, any study designed to report outcomes for patients with ANSD and cochlear implantation should include: 1) a detailed clinical history from patient including any family history of peripheral neuropathy, vision loss, or vestibular deficits; 2) audiologic data: degree of hearing, age of onset, speech recognition scores in quiet and in noise; 3) electrophysiologic data: OAE, ABR, ECochG including CM, summating potential, auditory nerve neurophonic, and adaptation; 4) CI device implanted; and 5) widely used postimplant measures including word recognition scores in quiet and in noise. In addition, genetic data should also be available for these patients. Such detailed information will aid in comparisons between studies for these relatively rare disorders in the future.

Another complicating factor in studying ANSD is that in approximately 20--30% of individuals with ANSD, the OAE response diminishes over time.[15](#lio2288-bib-0015){ref-type="ref"} This is certainly the case for the most studied gene, *OTOF*,[59](#lio2288-bib-0059){ref-type="ref"} but also appears to be the similar in other studied auditory synaptopathies and neuropathies.[15](#lio2288-bib-0015){ref-type="ref"}, [59](#lio2288-bib-0059){ref-type="ref"} This has implications for the evaluation of noncongenital cases and adults with deafness. In many instances, the physiologic determinates currently used to diagnose auditory neuropathy, namely OAE, may therefore not be available. The cochlear microphonic is another physiologic measure to evaluate for ANSD, but this test is currently not used for screening. This underscores the importance of molecular genetic testing for individuals, including newborns and children, as well as adults, who are undergoing cochlear implantation.

Further research is also needed on the effects of genetic lesions to the auditory cortex. Several known deafness genes have known effects on the midbrain and auditory cortex, including *DFNB59*, *CACNA1D*, and *KCNQ4*.[110](#lio2288-bib-0110){ref-type="ref"} Two genes known to be involved in the hair cell tip‐link, *PCDH15* and *CDH23* also are required for interneuron development in the auditory cortex in mice.[111](#lio2288-bib-0111){ref-type="ref"} Further research is required to determine if mutations in these genes affect CI outcomes due to lesions in central auditory circuits.

From a practical standpoint, the advances in our understanding of CIs and ANSD presented in this review will generally not alter patient care by CI surgeons today. However, in the near future, as more tailored CI devices and molecular therapies emerge an understanding of site of lesion to the auditory system will be crucial. Today, CI surgeons can consider the effect of genetic or other lesions to the auditory nerve when counseling patients about CI outcomes. However, at the current stage of research, even for patients with mutations affecting the auditory nerve, a CI would still be recommended given improved hearing outcomes in almost all patients with a CI. CI surgeons are encouraged to pursue genetic testing in evaluation of deafness, particularly children, as recommended by recent guidelines.[112](#lio2288-bib-0112){ref-type="ref"} To evaluate for mutations affecting the auditory nerve or synapse, a multigene comprehensive panel would be required as the genes discussed above are not typically included in single gene tests.[113](#lio2288-bib-0113){ref-type="ref"} Importantly, the CI surgeon should keep in mind that the site of lesion will not be the only determinate of CI outcome, as even two siblings with the same mutation causing ANSD can have markedly different audiologic measures and CI outcomes.[57](#lio2288-bib-0057){ref-type="ref"}

A paradigm has emerged where the CI surgeon needs to consider not only clinical factors such as type and duration of deafness but molecular and physiology factors such as the health of the cochlea, synapse, spiral ganglion, and auditory nerve to provide the best outcomes for patients. This evaluation typically begins with molecular diagnosis of deafness and will often require multidisciplinary discussion with audiologists and geneticists. As our understanding of the physiology of hearing and CIs has improved, the importance of these factors becomes even more apparent. Such research lays the groundwork for targeted molecular therapies as well as custom CIs tailored to a specific site of lesion.
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